Considering that there may be significant differences in the nutritional status and the inflammatory status between patients with early-stage and middle-advanced lung cancer, Cox regression analysis was performed for patients with stage I–II and stage III NSCLC in order to further evaluate the potential prognostic value of FAR, SII, and AAPR in patients with different stages of the disease.
← all excerpts
Fibrinogen-to-albumin ratio (FAR) is the best biomarker for the overall survival of patients with non-small-cell lung cancer.
1
—
—